Baopharma 宝济药业
Shanghai, China baopharma.com
From their website, Nov 2026
Work here? Claim this listing
- GMP
About
Baopharma 宝济药业 develops recombinant protein and antibody-based therapeutics. It works on industrialization and commercialization of these products for patients, with operations in Shanghai and Suzhou, China.
Services
Recombinant human hyaluronidase solutions
Develops recombinant human hyaluronidase for subcutaneous drug delivery and combination use with small molecules and biologics.
Recombinant IgG cleaving enzyme development
Develops an IgG-degrading enzyme platform for rapidly cleaving circulating and tissue IgG in conditions such as autoimmune disease, transplantation, and gene therapy.
Recombinant chymotrypsin products
Develops recombinant chymotrypsin using genetic engineering to replace traditional animal organ extraction methods.
Biopharmaceutical manufacturing
Builds cGMP-compliant manufacturing for drug substance and finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes.
Drug substance production
Operates production lines using mammalian cell expression systems and bacterial/yeast expression systems.
Recombinant chymotrypsin development
Uses genetic engineering to develop chymotrypsin products as an alternative to traditional animal organ extraction methods.
Bispecific antibody formulation development
Develops KJ015, an anti-HER2 bispecific antibody formulated with Hysorptase for subcutaneous administration.
Biologics manufacturing
Manufactures therapeutic biological products using mammalian cell expression systems and bacterial/yeast expression systems.
Finished dosage form production
Produces injectable solutions, lyophilized powder injections, and pre-filled syringes.
Clinical development support
Advances products through clinical trial approvals and clinical trial programs in China and other regions.
- Turnaround
- Within 1 to 2 hours
- What to send
- Contact mailbox · Contact number · Message content
Capabilities
- Assays and studies
- Antibodies · Bispecifics · Small molecules · Mammalian expression · Lyophilization · Clinical trials · Phase I clinical trials
- Scale and capacity
- Approximately 63,000 square meters · 94 mu · 25,000-square-meter facility · Approximately 63,000 square meters facility · 94 mu (approx. 15.5 acres) of land
- Therapeutic areas
- Autoimmune diseases · Rare diseases · Organ transplantation · Gene therapy · Solid tumors · IgG-type multiple myeloma · Kidney transplantation · Anti-GBM disease · Kidney transplant · HER2-positive cancers · Multiple myeloma
Modalities and species
- Modalities
- Small molecule · Antibody · Bispecific · Recombinant protein
- Species and models
- Mammalian cell expression systems · Bacterial expression systems · Yeast expression systems · Streptococcus pyogenes
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: manufacturing facility
Industries served
- Biotech
- Pharmaceuticals
Company
- Type
- CDMO
- Founded
- 2011
Locations
- Address
- 50 Luoxin Road from Shanghai Jingfeng Pharmaceutical Co., Ltd. in October 2021, enab
- Sites
- Shanghai, China · Suzhou, China
- Serves
- China, New Zealand, Europe
Contacts
- Phone
- +86-21-56696602
Similar labs
Work here? Claim this listing